BioCorRx Inc. (OTCMKTS:BICX) Talks about BICX104 Human Trials and 2B3D Metaverse Partnership in The Stock Day Podcast
Shares of BioCorRx Inc. (OTCMKTS:BICX) have been moving within a narrow range over the past weeks. However, the stock could be in action as the company’s CEO and CFO Lourdes Felix, joined Stock Day host Everett Jolly.
Market Stats
On Wednesday, BICX stock ended flat at $2.45 with 600 shares, compared to its average volume of 1.1K shares. The stock moved within a range of $2.4500 – 2.4500 after opening trading at $2.46.
About The Company
BioCorRx Inc. (OTCMKTS:BICX) is an addiction treatment solutions company that uses unconventional methods to treat substance use and other related disorders. For instance, Beat Addiction Recovery is a substance use disorder recovery program that typically includes BioCorRx’s proprietary Cognitive Behavioral Therapy (CBT) modules. It also has peer support via a mobile app along with medication prescribed by an independent treating physician at their discretion. Its UnCraveRx Weight Loss Program is a medication-assisted weight loss program that gives access to concierge on-demand wellness specialists, such as nutritionists, fitness experts, and personal support from behavioral experts.
BioCorRX Inc. Discusses BICX104 Human Trials and 2B3D Metaverse Partnership with The Stock Day Podcast
The Stock Day Podcast saw the CEO and CFO of BioCorRx Inc., Lourdes Felix joining host Everett Jolly. In answer to the company’s background and existing projects, Felix replied that BioCorRx is a hybrid of healthcare and biotechnology. As of now, they have two programs – one for substance use disorder and alcoholism, and another for a weight loss program that was launched three years back.
Felix also spoke about their R&D division, which is their subsidiary BioCorRx Pharmaceuticals where they are taking the main product pipeline, BICX104, through regulatory approval. She said that the regulatory process for BICX104 began back in February 2019. The pre-clinical study phase was successfully completed in the 1st quarter of 2021, and the IND was then filed with the FDA in the 2nd quarter of 2022 in May. They are now moving into the next phase, which are human trials.
Copley touched on the company’s Beat Addiction Recovery program as well. Felix talked about the importance of (VR) virtual reality and its use for effective mental health assessments and treatments within a virtual world created by a physician. She confirmed that they are collaborating with a company called 2B3D. They have even created a Metaverse platform that incorporates the ability to seek out mental health treatments into a gamified or virtual reality world.
Ultimate Objective
The ultimate objective is to help their veterans, as many suffer from Post Traumatic Stress Syndrome (PTSD). This technology lets them approach mental health professionals using a personalized online interaction. It is accessible to them, regardless of their location. On being asked how the company has been affected since the start of the pandemic, she said that things are slowly becoming normal because they can now travel and attend events in person. She is hopeful that things seem good and that there is much to look forward to.
Felix then spoke about BioCorRX’s unique Beat Addiction Recovery program, which combines medication and cognitive behavioral therapy (CBT). There are to be several aspects of the CBT that will be incorporated into the Metaverse platform that 2B3D has created.
Key Quote
Copley began the interview by asking about the Company’s background and current projects. “BioCorRx is a hybrid of healthcare and biotechnology,” explained Felix. “We have a couple of programs, including one for substance use disorder and alcoholism, as well as a weight loss program that we developed and launched three years ago,” she continued. “We also have our R&D division, which is our subsidiary BioCorRx Pharmaceuticals where we are taking our main product pipeline, BICX104, through regulatory approval.”
Traders Corner
BICX stock is trading below the 20-Day and 50-Day Moving averages of $2.43 and $2.61 respectively. Moreover, the stock is trading below the 200-Day moving average of $3.70.
